Streetbeat News

Products Services

SPRY

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) announced that clinical data supporting neffy (epinephrine nasal spray) will be presented at the 2023 American College of Allergy Asthma and Immunology (ACAAI) Annual Scientific Meeting. The data suggests that neffy could be a safe and effective option for treating severe allergic reactions across various patient subgroups. Notably, the pharmacokinetics of neffy are independent of BMI or body weight, unlike injection products.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 4:05 pm

LYFT

EVCS and Lyft Inc. (NASDAQ:LYFT) have announced a new partnership program that offers discounted charging on the EVCS network for Lyft's EV drivers. The program is available to all EV drivers on Lyft and covers all EVCS publicly accessible charging stations across California, Oregon, and Washington. The program aims to accelerate the transition to clean transportation in these states and aligns with California's Clean Miles Standard, which mandates 90% of rideshare vehicle miles traveled to be zero-emissions by 2030.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 4:04 pm

LLY

NVO

SNY

UNH

Optum Rx, a pharmacy services company, is taking additional steps to make insulin more affordable. Starting from Jan. 1, 2024, it will place eight preferred insulin products on tier one of standard commercial formularies, limiting out-of-pocket spend to $35 or less. This move is part of Optum Rx's ongoing efforts to improve access and make critical medications more affordable. The products of three manufacturers, including Eli Lilly, Novo Nordisk, and Sanofi, will be added to tier one. Optum Rx also supported UnitedHealthcare in eliminating copays for consumers in group fully insured plans for insulin and other critical drugs.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:55 pm

BMY

The U.S. FDA has accepted for priority review Bristol Myers Squibb's application for Breyanzi for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The application is based on results from the TRANSCEND CLL 004 trial, which showed clinical benefit with a CAR T cell therapy in heavily pre-treated patients. The FDA has assigned a target action date of March 14, 2024. If approved, Breyanzi would be the first and only CAR T cell therapy available for this patient population.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:14 pm

VLKAF

VWAGY

A senior executive at Volkswagen has announced plans to introduce an electric vehicle (EV) priced under $35,000 to the US market in the next 3-4 years. The company is considering building the EV in the US or Mexico and is also exploring the possibility of localizing the assembly of battery packs for the vehicle. The executive emphasized that Volkswagen is not scaling back its plans in the US market.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:58 pm

NIO

NIO USA CEO has stated that the company sees 'Immersive User Experience' as a brand differentiator, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:50 pm

NIO

NIO's CEO has stated that the company is still considering its entry into the North American market by 2025. The company is open to any kind of partnerships in North America and acknowledges the need to build infrastructure before bringing its electric vehicles to the region.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:50 pm

BAYRY

RXRX

Bayer and Recursion have announced a research collaboration focusing on oncology. The partnership will leverage Bayer's small molecule compound library and expertise in biology and medicinal chemistry, as well as Recursion's AI-guided drug discovery platform.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:44 pm

AMD

ASML

NVDA

QCOM

SSNLF

Micron Technology's stock is trading higher amid reports of the company showcasing its latest technologies at the China International Import Expo. Despite a previous sales ban, Micron is making its debut at the expo, implying its attempts to improve its relations with China. Other chip-related companies, including Qualcomm, ASML Holding, and Samsung Electronics, are also demonstrating their latest technologies. Nvidia Corp, however, continues its absence from the event due to the U.S. trade embargo.

Portfolio Pulse from Anusuya Lahiri

November 09, 2023 | 2:34 pm

FXI

NVDA

Nvidia Corp. is set to release three new artificial intelligence chips for China, following the US's further restriction on the Asian nation's access to advanced semiconductors. The chips are based on the design of Nvidia's flagship H100 product. Chinese firms are expected to receive the chips in the coming days. Following the report, Chinese server supplier IEIT Systems Co. saw its stock rise by 10%.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:34 pm